Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal bupivacaine (Pacira BioSciences)
- Development stage
- Unknown
- Lead developer
- Pacira BioSciences
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Local Infiltration, Nerve Block
01
Overview
Liposomal bupivacaine is an extended-release formulation of the amide-type local anesthetic bupivacaine, utilizing DepoFoam multivesicular liposome technology. It is designed to provide prolonged postsurgical analgesia for up to 72 hours by slowly releasing the active ingredient into the surgical site or near nerves, thereby reducing the need for systemic opioids. The mechanism of action involves the reversible blockade of voltage-gated sodium channels on neuronal membranes, which prevents the generation and conduction of nerve impulses and inhibits pain signal transmission. This specific clinical context involves a study by the University of Texas at Austin evaluating its efficacy as a V2 trigeminal nerve block within an Enhanced Recovery After Surgery (ERAS) protocol for patients undergoing orthognathic surgery.
- Brand names
- Exparel
- Other names
- LBbupivacaine liposome injectable suspension
02
Targets
SCN5A (Sodium channel protein type 5 subunit alpha)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on liposomal bupivacaine (Pacira BioSciences).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal bupivacaine (Pacira BioSciences).